trial

Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia

NCTId NCT00604760
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Unknown
Enrollment 160 (estimated)
Sponsored by Memory Pharmaceuticals
Primary completion 2009-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Unknown
Enrollment
160 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2007-12
Primary completion
2009-02
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
MEM 3454

Sponsors

Memory PharmaceuticalsLead Sponsor

Sites

44 total
Lemon Grove, United StatesNewport Beach, United StatesOceanside, United StatesPasadena, United StatesRosemead, United StatesSan Diego, United StatesSanta Ana, United StatesSanta Ana, United StatesTorrance, United StatesAventura, United StatesFort Lauderdale, United StatesMiami, United States

Linked catalysts

1
Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in — primary completion2009-02

Facts & assertions

4 sourced
Enrollment
160
Phase
PHASE2
Primary Completion Date
2009-02
Status
UNKNOWN
relationships
The graph out of here
drug
MEM 3454
drug
lead_sponsor
Memory Pharmaceuticals
company
indication
Cognitive Impairment Associated With Schizophrenia
indication